SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vascular Solutions, Inc.(VASC) Stopping Their Red Ink and Bl -- Ignore unavailable to you. Want to Upgrade?


To: Arthur Radley who wrote (6)5/2/2005 10:29:08 AM
From: Arthur Radley  Read Replies (1) | Respond to of 22
 
Vascular Solutions (VASC)
9:42 AM ET May 2, 2005
Adams Harkness initiates BUY. Target $15. Adams Harkness initiates VASC as they estimate the co can drive a two-year revenue CAGR of 40% from 2004 to 2006, given the early stage of existing products, the full product pipeline, and the expanding sales force. They cite catalysts as: 1) continued strong growth in the hemostasis, manual thrombus aspiration, and laser varicose vein markets; 2) a host of product introductions expected in 2H05 and 2006; 3) expanding usage driven by clinical data; 4) nearing profitability with a strong balance sheet; and 5) increasing Street coverage.